{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:20Z","timestamp":1792788080727,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-05156-2","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:13:54Z","timestamp":1784970834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world injection burden, treatment switching, and visual outcomes in diabetic macular edema: a 563-eye cohort study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0513-6065","authenticated-orcid":false,"given":"Hasan","family":"\u00d6nc\u00fcl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7866-7898","authenticated-orcid":false,"given":"Umut","family":"Da\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5177-2227","authenticated-orcid":false,"given":"H\u00fcseyin","family":"Din\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1588-7869","authenticated-orcid":false,"given":"Mehmet Fuat","family":"Alaku\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"5156_CR1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JWY Yau","year":"2012","unstructured":"Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556\u201364.","journal-title":"Diabetes Care"},{"key":"5156_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","volume":"376","author":"N Cheung","year":"2010","unstructured":"Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124\u201336.","journal-title":"Lancet"},{"key":"5156_CR3","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy. N Engl J Med. 1994;331:1480\u20137.","journal-title":"N Engl J Med"},{"key":"5156_CR4","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","volume":"117","author":"MJ Elman","year":"2010","unstructured":"Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Diabetic Retinopathy Clinical Research Network (DRCR.net). Randomized trial evaluating ranibizumab plus prompt or deferred laser for diabetic macular edema. Ophthalmology. 2010;117:1064\u201377.","journal-title":"Ophthalmology"},{"key":"5156_CR5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from RISE and RIDE studies. Ophthalmology. 2012;119:789\u2013801.","journal-title":"Ophthalmology"},{"key":"5156_CR6","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema: VIVID and VISTA studies. Ophthalmology. 2016;123:2376\u201385.","journal-title":"Ophthalmology"},{"key":"5156_CR7","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193\u2013203.","journal-title":"N Engl J Med"},{"key":"5156_CR8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.ajo.2013.12.018","volume":"157","author":"NM Holekamp","year":"2014","unstructured":"Holekamp NM, Liu Y, Yeh WS, Zlateva G, Quimbo R, Cutone J, et al. Clinical utilization of anti-VEGF therapy in retinal diseases. Am J Ophthalmol. 2014;157:825\u201333.","journal-title":"Am J Ophthalmol"},{"key":"5156_CR9","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00417-020-04798-2","volume":"258","author":"C Ehlken","year":"2020","unstructured":"Ehlken C, Ziemssen F, Eter N, Lanzl I, Kaymak H, Lommatzsch A, et al. Non-adherence and non-persistence in intravitreal treatment: a systematic review. Graefes Arch Clin Exp Ophthalmol. 2020;258:2077\u201390.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5156_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ajo.2018.08.004","volume":"195","author":"E Maggio","year":"2018","unstructured":"Maggio E, Sartore M, Attanasio M, Midena E, Pilotto E, Parolini B, et al. Anti-VEGF treatment for diabetic macular edema in a real-world clinical setting. Am J Ophthalmol. 2018;195:209\u201322.","journal-title":"Am J Ophthalmol"},{"key":"5156_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ajo.2016.09.002","volume":"172","author":"NV Patrao","year":"2016","unstructured":"Patrao NV, Antao S, Egan C, Omar A, Hamilton R, Hykin P, et al. Real-world outcomes of ranibizumab treatment for diabetic macular edema. Am J Ophthalmol. 2016;172:51\u20137.","journal-title":"Am J Ophthalmol"},{"key":"5156_CR12","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","volume":"121","author":"RL Johnston","year":"2014","unstructured":"Johnston RL, Carius HJ, Skelly A, Ferreira A, Milnes F, et al. UK Age-Related Macular Degeneration EMR Users Group. Real-world data in anti-VEGF therapy. Ophthalmology. 2014;121:1092\u2013101.","journal-title":"Ophthalmology"},{"key":"5156_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/bjophthalmol-2015-308166","volume":"100","author":"FG Holz","year":"2016","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Key drivers of visual acuity gains in neovascular AMD: AURA study. Br J Ophthalmol. 2016;100:162\u20138.","journal-title":"Br J Ophthalmol"},{"key":"5156_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/bjophthalmol-2016-309313","volume":"101","author":"C Egan","year":"2017","unstructured":"Egan C, Zhu H, Lee A, Sim DA, Mitry D, Bailey C, et al. Diabetic retinopathy EMR users group report. Br J Ophthalmol. 2017;101:75\u201380.","journal-title":"Br J Ophthalmol"},{"key":"5156_CR15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","volume":"132","author":"JK Sun","year":"2014","unstructured":"Sun JK, Lin MM, Lammer J, Prager S, Sarangi R, Silva PS, et al. Disorganization of retinal inner layers as a biomarker. JAMA Ophthalmol. 2014;132:1309\u201316.","journal-title":"JAMA Ophthalmol"},{"key":"5156_CR16","first-page":"1504","volume":"38","author":"R Das","year":"2018","unstructured":"Das R, Spence G, Hogg RE, Stevenson M, Chakravarthy U, Tufail A, et al. Optical coherence tomography biomarkers and visual outcomes. Retina. 2018;38:1504\u201313.","journal-title":"Retina"},{"key":"5156_CR17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.oret.2018.10.006","volume":"3","author":"CC Wykoff","year":"2019","unstructured":"Wykoff CC, Clark WL, Nielsen JS, Brill JV, Greene LS, Heggen CL, et al. Treat-and-extend management of diabetic macular edema. Ophthalmol Retina. 2019;3:252\u201360.","journal-title":"Ophthalmol Retina"},{"key":"5156_CR18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"DM Brown","year":"2020","unstructured":"Brown DM, Wykoff CC, Wong TP, Croft DE, Schuetzle KL, Clark WL, et al. Longer-acting anti-VEGF therapy for DME. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05156-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05156-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05156-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:01:45Z","timestamp":1792785705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05156-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5156"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-05156-2","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"29 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the Institutional Review Board (Ethics Committee) of Health Sciences University Diyarbak\u0131r Gazi Ya\u015fargil Training and Research Hospital (Protocol code: 800; Approval date: 19 December 2025). The study adhered to the tenets of the Declaration of Helsinki. Due to the retrospective nature of the study, the requirement for informed consent was waived by the Ethics Committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"676"}}